famotidine has been researched along with Esophageal Reflux in 61 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results indicate that hydrotalcite relieves the symptoms of gastroesophageal reflux faster than OTC famotidine and is equally effective for up to two hours." | 9.12 | The efficacy of hydrotalcite compared with OTC famotidine in the on-demand treatment of gastroesophageal reflux disease: a non-inferiority trial. ( Beneke, M; Konturek, JW; Koppermann, R; Petersen-Braun, M; Weingärtner, U, 2007) |
| " Fifty-four gastro-oesophageal reflux disease patients were assigned to treatment with famotidine at a dosage of 20 mg twice daily; or omeprazole, 20 mg once daily, for a period of 8 weeks." | 9.11 | Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease. ( Fujita, F; Itoh, K; Itoh, M; Joh, T; Kataoka, H; Kubota, E; Mori, Y; Nakao, H; Ogasawara, N; Ohara, H; Oshima, T; Sasaki, M; Sobue, S; Tanida, S; Togawa, S; Wada, T; Yamada, T, 2005) |
| "Omeprazole is more effective than famotidine for the control of gastro-oesophageal reflux disease symptoms in H." | 9.11 | Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease. ( Arakawa, T; Chono, S; Fujiwara, Y; Higuchi, K; Kitada, K; Kobayashi, K; Nakagawa, K; Nebiki, H; Oshitani, N; Satoh, H; Tominaga, K; Uno, H; Watanabe, T, 2005) |
| "There is a disclosure of the results of the therapy of gastroesophageal reflux disease at the stage of reflux esophagitis with gastrosidin (famotidine), 40 mg twice a day during 4-8 weeks." | 9.10 | [Efficacy of gastrosidine (famotidine) in the treatment of gastroesophageal reflux at the reflux esophagitis stage]. ( Li, IA; Vasil'ev, IuV, 2002) |
| "To evaluate the safety and efficacy of famotidine for infant gastro-oesophageal reflux disease." | 9.10 | Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. ( Ahrens, SP; Czinn, SJ; Devandry, SN; Dice, JE; Liacouras, CA; Orenstein, SR; Shalaby, TM; Simon, TJ; Stauffer, LA, 2003) |
| "The aim of this study was to measure the efficacy of 150-mg ranitidine effervescent tablets compared with 20-mg famotidine wafers in the management of patients presenting to primary care physicians with episodic symptoms of gastro-oesophageal reflux disease (GORD)." | 9.08 | Ranitidine effervescent and famotidine wafer in the relief of episodic symptoms of gastro-oesophageal reflux disease. ( Engzelius, JM; Kjaersgaard, P; Knapstad, LJ; Solhaug, JH, 1997) |
| "180 patients suffering from frequent heartburn and endoscopically normal oesophageal mucosa or mild non-erosive oesophagitis entered an open, multicentre study to evaluate the 6-week safety profile and efficacy on symptom relief of famotidine (CAS 76824-35-6, Pepdul mite), a potent and long-acting H2-receptor antagonist." | 9.08 | [Symptomatic therapy with famotidine in non-erosive gastro-esophageal reflux. Results of an open multicenter study]. ( Heckers, H; Lübbecke, F, 1995) |
| "This US multicentre, randomized, double-blind, placebo-controlled, parallel group study determined the effects of two twice daily oral famotidine regimens on symptom relief and healing of erosive oesophagitis in patients with gastro-oesophageal reflux disease." | 9.07 | Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive oesophagitis. ( Berenson, MM; Berlin, RG; Cagliola, A; Simon, TJ; Snapinn, S, 1994) |
| "We conducted a double-blind, placebo-controlled, multicenter trial comparing the efficacy of famotidine 40 mg administered at bedtime (HS), 20 mg given twice daily (BID), and placebo to relieve heartburn and to heal endoscopically documented esophageal erosions or ulcerations." | 9.07 | Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group. ( Berlin, RG; Bradstreet, DC; Humphries, TJ; Sabesin, SM; Walton-Bowen, KL; Zaidi, S, 1991) |
| "The present study attempts to assess the alteration in patterns of gastro-oesophageal reflux as assessed by 24-h oesophageal pH monitoring by varying degrees of H2-receptor blockade with famotidine." | 9.06 | Dose--response effect of famotidine on patterns of gastro-oesophageal reflux. ( Antonello, J; Cagliola, A; Humphries, TJ; Orr, WC; Robinson, MG, 1988) |
| "Famotidine, a potent and long-acting H2-receptor antagonist, has been evaluated in patients with gastroesophageal reflux disease (GERD)." | 8.78 | Famotidine in gastroesophageal reflux disease (GERD). ( Wesdorp, IC, 1992) |
| "To investigate the effect of famotidine on gastroesophageal reflux (GER) and duodeno-gastro-esophageal reflux (DGER) and to explore it's possible mechanisms." | 7.72 | The effect of famotidine on gastroesophageal and duodeno-gastro-esophageal refluxes in critically ill patients. ( Dai, N; Si, JM; Wang, JG; Xin, Y; Zhao, L, 2003) |
| "Lansoprazole was superior to famotidine in reducing the thickness of esophageal wall." | 6.69 | Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux. ( Aibe, T; Eto, S; Fujisaki, T; Iida, T; Matsuoka, H; Mine, S; Morimoto, I; Tabata, T; Tanaka, Y; Yamada, S, 2000) |
| "All had classic symptoms of gastro-oesophageal reflux but normal results of upper gastrointestinal endoscopy and oesophageal mucosal histological tests." | 6.67 | Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease. ( de Caestecker, JS; Marrero, JM; Maxwell, JD, 1994) |
| " Most studies have documented the need for multiple daily dosing with H2-antagonists to achieve clinical and statistical efficacy for symptom relief." | 6.67 | Famotidine (20 mg) b.d. relieves gastrooesophageal reflux symptoms in patients without erosive oesophagitis. Famotidine/GERD Investigation Group. ( Barden, P; Decktor, DL; Holt, S; Hufnagel, K; Humphries, TJ; Moyer, R; Pevelery, M; Robinsen, M; Root, J; Stone, RC, 1991) |
| "Famotidine has been used for the treatment of peptic ulcers and Zollinger Ellison syndrome and is also useful in reflux and erosive oesophagitis." | 5.29 | Famotidine in the management of gastro-oesophageal reflux. ( Dubois, C; Lule, GN; Ogutu, EO; Okoth, FA; Pilczer, S, 1994) |
| "To investigate whether histamine H2-receptor antagonists are sufficient to treat heartburn in nonerosive reflux disease in Japanese, who produce less gastric acid than Westerners, the efficacy of famotidine in Japanese nonerosive reflux disease patients was studied in a double-blind, placebo-controlled, parallel group-comparative, multicenter study." | 5.13 | A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease. ( Haruma, K; Hongo, M; Kinoshita, Y, 2008) |
| " Fifty-four gastro-oesophageal reflux disease patients were assigned to treatment with famotidine at a dosage of 20 mg twice daily; or omeprazole, 20 mg once daily, for a period of 8 weeks." | 5.11 | Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease. ( Fujita, F; Itoh, K; Itoh, M; Joh, T; Kataoka, H; Kubota, E; Mori, Y; Nakao, H; Ogasawara, N; Ohara, H; Oshima, T; Sasaki, M; Sobue, S; Tanida, S; Togawa, S; Wada, T; Yamada, T, 2005) |
| "Omeprazole is more effective than famotidine for the control of gastro-oesophageal reflux disease symptoms in H." | 5.11 | Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease. ( Arakawa, T; Chono, S; Fujiwara, Y; Higuchi, K; Kitada, K; Kobayashi, K; Nakagawa, K; Nebiki, H; Oshitani, N; Satoh, H; Tominaga, K; Uno, H; Watanabe, T, 2005) |
| " We investigated the heartburn symptoms of patients with gastro-oesophageal reflux disease during sequential treatment with 40 mg of famotidine or 15 mg of lansoprazole to clarify whether H." | 5.11 | Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole. ( Adachi, K; Amano, Y; Fujishiro, H; Furuta, K; Hashimoto, T; Hattori, S; Ishihara, S; Kinoshita, Y; Komazawa, Y; Mihara, T, 2005) |
| "Heartburn, regurgitation and dysphagia were hardly found in any group at 8 weeks after 15 mg or 30 mg lansoprazole treatment." | 5.11 | Management of symptoms in step-down therapy of gastroesophageal reflux disease. ( Iida, T; Kishikawa, H; Mine, S; Tabata, T; Tanaka, Y, 2005) |
| "There is a disclosure of the results of the therapy of gastroesophageal reflux disease at the stage of reflux esophagitis with gastrosidin (famotidine), 40 mg twice a day during 4-8 weeks." | 5.10 | [Efficacy of gastrosidine (famotidine) in the treatment of gastroesophageal reflux at the reflux esophagitis stage]. ( Li, IA; Vasil'ev, IuV, 2002) |
| "To evaluate the safety and efficacy of famotidine for infant gastro-oesophageal reflux disease." | 5.10 | Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. ( Ahrens, SP; Czinn, SJ; Devandry, SN; Dice, JE; Liacouras, CA; Orenstein, SR; Shalaby, TM; Simon, TJ; Stauffer, LA, 2003) |
| "The aim of this study was to measure the efficacy of 150-mg ranitidine effervescent tablets compared with 20-mg famotidine wafers in the management of patients presenting to primary care physicians with episodic symptoms of gastro-oesophageal reflux disease (GORD)." | 5.08 | Ranitidine effervescent and famotidine wafer in the relief of episodic symptoms of gastro-oesophageal reflux disease. ( Engzelius, JM; Kjaersgaard, P; Knapstad, LJ; Solhaug, JH, 1997) |
| "180 patients suffering from frequent heartburn and endoscopically normal oesophageal mucosa or mild non-erosive oesophagitis entered an open, multicentre study to evaluate the 6-week safety profile and efficacy on symptom relief of famotidine (CAS 76824-35-6, Pepdul mite), a potent and long-acting H2-receptor antagonist." | 5.08 | [Symptomatic therapy with famotidine in non-erosive gastro-esophageal reflux. Results of an open multicenter study]. ( Heckers, H; Lübbecke, F, 1995) |
| "This US multicentre, randomized, double-blind, placebo-controlled, parallel group study determined the effects of two twice daily oral famotidine regimens on symptom relief and healing of erosive oesophagitis in patients with gastro-oesophageal reflux disease." | 5.07 | Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive oesophagitis. ( Berenson, MM; Berlin, RG; Cagliola, A; Simon, TJ; Snapinn, S, 1994) |
| "We conducted a double-blind, placebo-controlled, multicenter trial comparing the efficacy of famotidine 40 mg administered at bedtime (HS), 20 mg given twice daily (BID), and placebo to relieve heartburn and to heal endoscopically documented esophageal erosions or ulcerations." | 5.07 | Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group. ( Berlin, RG; Bradstreet, DC; Humphries, TJ; Sabesin, SM; Walton-Bowen, KL; Zaidi, S, 1991) |
| "The present study attempts to assess the alteration in patterns of gastro-oesophageal reflux as assessed by 24-h oesophageal pH monitoring by varying degrees of H2-receptor blockade with famotidine." | 5.06 | Dose--response effect of famotidine on patterns of gastro-oesophageal reflux. ( Antonello, J; Cagliola, A; Humphries, TJ; Orr, WC; Robinson, MG, 1988) |
| "Twenty-four-hour gastric and esophageal pH were monitored simultaneously in 19 patients with moderate esophagitis before and after a randomized crossover treatment with 40 mg famotidine or 300 mg ranitidine." | 5.06 | Gastric and esophageal acidity during continuous treatment with H2-antagonists in uncomplicated esophagitis. ( Abbritti, F; Fiorucci, S; Morelli, A; Perrone, E; Santucci, L, 1989) |
| " We report 3 cases of anaphylactic reactions induced by lansoprazole or ranitidine diagnosed in a population of 8304 first-referral patients over a 13-year period." | 4.83 | Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature. ( Bozkurt, B; Demirkan, K; Kalyoncu, AF; Karakaya, G, 2006) |
| "Famotidine, a potent and long-acting H2-receptor antagonist, has been evaluated in patients with gastroesophageal reflux disease (GERD)." | 4.78 | Famotidine in gastroesophageal reflux disease (GERD). ( Wesdorp, IC, 1992) |
| "A 59-year-old man was orally administered rabeprazole, a proton pump inhibitor (PPI), for gastroesophageal reflux disease, after which he gradually developed iron-deficiency anemia." | 3.80 | Iron-deficiency anemia caused by a proton pump inhibitor. ( Chonan, A; Hashimoto, R; Matsuda, T, 2014) |
| "Ten male patients with GERD symptoms and abnormal gastroesophageal reflux were investigated by pH monitoring on days 1 and 15 of continuous oral famotidine administration at 20 mg twice daily, and H." | 3.73 | Tolerance to H2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease. ( Adachi, K; Azumi, T; Fujisawa, T; Furuta, K; Katsube, T; Kinoshita, Y; Komazawa, Y; Mihara, T; Miki, M, 2006) |
| "To investigate the effect of famotidine on gastroesophageal reflux (GER) and duodeno-gastro-esophageal reflux (DGER) and to explore it's possible mechanisms." | 3.72 | The effect of famotidine on gastroesophageal and duodeno-gastro-esophageal refluxes in critically ill patients. ( Dai, N; Si, JM; Wang, JG; Xin, Y; Zhao, L, 2003) |
| "15 healthy Japanese volunteers were dosed for 7 days in a four-way random crossover trial with 100 mg entero-coated type aspirin only once daily, 100 mg aspirin + 20 mg famotidine twice daily, 15 mg lansoprazole once daily, or 10 mg rabeprazole once daily." | 2.77 | Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin. ( Furuta, T; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Uotani, T; Yamade, M, 2012) |
| "Mucosal injury caused by gastroesophageal reflux may result in changes in esophageal mucosal blood flow." | 2.73 | Increased esophageal mucosal/submucosal blood flow in patients with gastroesophageal reflux disease: normalization by treatment with a proton pump inhibitor. ( Iida, T; Mine, S; Okada, Y; Tabata, T; Tanaka, Y, 2008) |
| "5 mg/kg intravenously were divided into two groups by age, and pharmacokinetic parameters in infants 0-3 months and >3 to 12 months of age were compared." | 2.71 | Pharmacokinetics of famotidine in infants. ( Baier, J; Blumer, JL; Eisenhandler, R; James, LP; Kearns, GL; Marshall, JD; Murphy, MG; Panebianco, DL; Scheimann, AO; Wenning, LA; Yeh, KC; Zhong, L, 2005) |
| "Lansoprazole was superior to famotidine in reducing the thickness of esophageal wall." | 2.69 | Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux. ( Aibe, T; Eto, S; Fujisaki, T; Iida, T; Matsuoka, H; Mine, S; Morimoto, I; Tabata, T; Tanaka, Y; Yamada, S, 2000) |
| "Famotidine increased the lower esophagus sphincter pressure from the initial 2." | 2.68 | [The effect of cimetidine and famotidine on esophageal motility]. ( Paradowski, L; Salomon, A; Szelag, A, 1996) |
| " Most studies have documented the need for multiple daily dosing with H2-antagonists to achieve clinical and statistical efficacy for symptom relief." | 2.67 | Famotidine (20 mg) b.d. relieves gastrooesophageal reflux symptoms in patients without erosive oesophagitis. Famotidine/GERD Investigation Group. ( Barden, P; Decktor, DL; Holt, S; Hufnagel, K; Humphries, TJ; Moyer, R; Pevelery, M; Robinsen, M; Root, J; Stone, RC, 1991) |
| "All had classic symptoms of gastro-oesophageal reflux but normal results of upper gastrointestinal endoscopy and oesophageal mucosal histological tests." | 2.67 | Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease. ( de Caestecker, JS; Marrero, JM; Maxwell, JD, 1994) |
| " Compared with other H2RAs, famotidine had the best short-term therapeutic effect in adults with GERD, especially at a dosage of 80 mg per day." | 2.53 | Comparative effectiveness of histamine-2 receptor antagonists as short-term therapy for gastro-esophageal reflux disease: a network meta-analysis. ( Liu, L; Wang, S; Wang, Y; Zhao, F, 2016) |
| "Lansoprazole was superior to famotidine with regard to both efficacy and cost-effectiveness and therefore is the preferred therapeutic agent for the maintenance treatment of GERD." | 2.42 | [Evaluation of the efficacy and the cost-effectiveness of maintenance treatment of gastroesophageal reflux disease: proton pump inhibitor versus histamine-2-receptor antagonist]. ( Habu, Y; Hayakumo, T; Kawai, K; Shio, S; Yoshino, T, 2004) |
| "A common condition, gastroesophageal reflux disease (GERD) involves the reflux of gastric contents into the esophagus." | 2.41 | Managing gastroesophageal reflux disease. ( Ch'ien, AP; Corey, RS; Ray, SW; Secrest, J, 2002) |
| " The ideal therapy for GORD will have linear pharmacokinetics, a relatively long plasma half-life (t1/2), a duration of action allowing once daily administration, and a stable effect independent of interactions with food, antacids and other drugs." | 2.39 | Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. ( Berstad, A; Hatlebakk, JG, 1996) |
| " Dosage requirements vary according to age and clinical condition, and children require a relatively higher drug dosage (mg/kg) than adults." | 2.39 | Do H2 receptor antagonists have a therapeutic role in childhood? ( Kelly, DA, 1994) |
| " While very safe, clinicians need to know correct dosing guidelines, drug interactions, and side effect profiles." | 2.38 | The clinical use of histamine-2 receptor antagonists. ( Michocki, RJ; Richardson, JP, 1992) |
| "Famotidine has since been shown to improve patient outcomes and reduce symptom severity in patients acutely ill with COVID-19." | 1.91 | Role of Famotidine and Other Acid Reflux Medications for SARS-CoV-2: A Pilot Study. ( Alnouri, G; Balouch, B; Sataloff, RT; Vontela, S; Yeakel, H, 2023) |
| "Gastroesophageal reflux (GER) is an important sequela of congenital diaphragmatic hernia (CDH) repair." | 1.36 | Physiological and clinical characteristics of gastroesophageal reflux after congenital diaphragmatic hernia repair. ( Fukuzawa, M; Kawahara, H; Kubota, A; Nakai, H; Nose, K; Okuyama, H; Yoneda, A, 2010) |
| "Gastroesophageal reflux and related symptoms rarely deteriorate to require additional treatment after GP in patients with NI." | 1.36 | Should fundoplication be added at the time of gastrostomy placement in patients who are neurologically impaired? ( Fukuzawa, M; Kawahara, H; Kubota, A; Mitani, Y; Nakai, H; Nose, K; Yoneda, A, 2010) |
| "In the GERD positive group, the incidence of acid reflux during waking hours was more frequent than during sleeping hours." | 1.35 | [Gastroesophageal reflux disease in preschool children with asthma]. ( Doi, S; Kameda, M; Nishikido, T; Takamatu, I; Yoshida, Y, 2008) |
| "The majority of gastro-oesophageal reflux disease (GERD) seems to be non-erosive reflux disease." | 1.33 | Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis. ( Hiraishi, H; Masuyama, H; Nakamura, T; Shirakawa, K; Sugaya, H; Terano, A, 2005) |
| "58 patients with gastroesophageal reflux (GER) and 18 patients with chronic gastroduodenitis (CGD) were examined using 24-h monitoring of intraesophageal pH." | 1.30 | [Role of 24 hour intraesophageal pH monitoring in diagnosis of gastroesophageal reflux and assessment of drug effectiveness]. ( Abidin, ZU; Ivashkin, VT; Okhlobystin, AV; Sheptulin, AA; Trukhmanov, AS, 1999) |
| "Famotidine has been used for the treatment of peptic ulcers and Zollinger Ellison syndrome and is also useful in reflux and erosive oesophagitis." | 1.29 | Famotidine in the management of gastro-oesophageal reflux. ( Dubois, C; Lule, GN; Ogutu, EO; Okoth, FA; Pilczer, S, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.28) | 18.7374 |
| 1990's | 21 (34.43) | 18.2507 |
| 2000's | 28 (45.90) | 29.6817 |
| 2010's | 7 (11.48) | 24.3611 |
| 2020's | 3 (4.92) | 2.80 |
| Authors | Studies |
|---|---|
| Balouch, B | 1 |
| Vontela, S | 1 |
| Yeakel, H | 1 |
| Alnouri, G | 1 |
| Sataloff, RT | 1 |
| Malone, RW | 1 |
| Kim, YD | 1 |
| Wang, J | 1 |
| Shibli, F | 1 |
| Poels, KE | 1 |
| Ganocy, SJ | 1 |
| Fass, R | 1 |
| Hashimoto, R | 1 |
| Matsuda, T | 1 |
| Chonan, A | 1 |
| Zhao, F | 1 |
| Wang, S | 1 |
| Liu, L | 1 |
| Wang, Y | 1 |
| Yoshida, Y | 1 |
| Kameda, M | 1 |
| Nishikido, T | 1 |
| Takamatu, I | 1 |
| Doi, S | 1 |
| Hongo, M | 1 |
| Kinoshita, Y | 5 |
| Haruma, K | 2 |
| Kawahara, H | 2 |
| Okuyama, H | 1 |
| Nose, K | 2 |
| Nakai, H | 2 |
| Yoneda, A | 2 |
| Kubota, A | 2 |
| Fukuzawa, M | 2 |
| Mitani, Y | 1 |
| Sugimoto, M | 1 |
| Nishino, M | 1 |
| Kodaira, C | 1 |
| Yamade, M | 1 |
| Uotani, T | 1 |
| Ikuma, M | 1 |
| Furuta, T | 1 |
| Sakurai, K | 1 |
| Nagahara, A | 1 |
| Inoue, K | 1 |
| Akiyama, J | 1 |
| Mabe, K | 1 |
| Suzuki, J | 1 |
| Habu, Y | 2 |
| Araki, A | 1 |
| Suzuki, T | 1 |
| Satoh, K | 1 |
| Nagami, H | 1 |
| Harada, R | 1 |
| Tano, N | 1 |
| Kusaka, M | 1 |
| Fujioka, Y | 1 |
| Fujimura, T | 1 |
| Shigeto, N | 1 |
| Oumi, T | 1 |
| Miwa, J | 1 |
| Miwa, H | 1 |
| Fujimoto, K | 1 |
| Özer, M | 1 |
| Duman, M | 1 |
| Taş, Ş | 1 |
| Demırcı, Y | 1 |
| Aydin, MF | 1 |
| Reyhan, E | 1 |
| Atici, AE | 1 |
| Bostanci, EB | 1 |
| Akoğlu, M | 1 |
| Genç, E | 1 |
| Kawano, S | 1 |
| Murata, H | 1 |
| Tsuji, S | 1 |
| Kubo, M | 1 |
| Tatsuta, M | 1 |
| Iishi, H | 1 |
| Kanda, T | 1 |
| Sato, T | 1 |
| Yoshihara, H | 1 |
| Masuda, E | 1 |
| Noguchi, M | 1 |
| Kashio, S | 1 |
| Ikeda, M | 1 |
| Kaneko, A | 1 |
| Vasil'ev, IuV | 1 |
| Li, IA | 1 |
| Xin, Y | 1 |
| Dai, N | 1 |
| Zhao, L | 1 |
| Wang, JG | 1 |
| Si, JM | 1 |
| Orenstein, SR | 1 |
| Shalaby, TM | 1 |
| Devandry, SN | 1 |
| Liacouras, CA | 1 |
| Czinn, SJ | 1 |
| Dice, JE | 1 |
| Simon, TJ | 2 |
| Ahrens, SP | 1 |
| Stauffer, LA | 1 |
| Herszényi, L | 1 |
| Yoshino, T | 1 |
| Shio, S | 1 |
| Hayakumo, T | 1 |
| Kawai, K | 1 |
| Ivanov, AN | 1 |
| Iakovenko, EP | 1 |
| Iakovenko, AV | 1 |
| Wenning, LA | 1 |
| Murphy, MG | 1 |
| James, LP | 1 |
| Blumer, JL | 1 |
| Marshall, JD | 1 |
| Baier, J | 1 |
| Scheimann, AO | 1 |
| Panebianco, DL | 1 |
| Zhong, L | 1 |
| Eisenhandler, R | 1 |
| Yeh, KC | 1 |
| Kearns, GL | 1 |
| Scarpignato, C | 1 |
| Wada, T | 1 |
| Sasaki, M | 1 |
| Kataoka, H | 1 |
| Tanida, S | 1 |
| Itoh, K | 1 |
| Ogasawara, N | 1 |
| Oshima, T | 1 |
| Togawa, S | 1 |
| Kubota, E | 1 |
| Yamada, T | 1 |
| Mori, Y | 1 |
| Fujita, F | 1 |
| Ohara, H | 1 |
| Nakao, H | 1 |
| Sobue, S | 1 |
| Joh, T | 1 |
| Itoh, M | 1 |
| Fujiwara, Y | 1 |
| Higuchi, K | 1 |
| Nebiki, H | 1 |
| Chono, S | 1 |
| Uno, H | 1 |
| Kitada, K | 1 |
| Satoh, H | 1 |
| Nakagawa, K | 1 |
| Kobayashi, K | 1 |
| Tominaga, K | 1 |
| Watanabe, T | 1 |
| Oshitani, N | 1 |
| Arakawa, T | 1 |
| Nakamura, T | 1 |
| Shirakawa, K | 1 |
| Masuyama, H | 1 |
| Sugaya, H | 1 |
| Hiraishi, H | 1 |
| Terano, A | 1 |
| Adachi, K | 3 |
| Komazawa, Y | 3 |
| Mihara, T | 3 |
| Azumi, T | 2 |
| Fujisawa, T | 2 |
| Katsube, T | 2 |
| Furuta, K | 3 |
| Hashimoto, T | 1 |
| Fujishiro, H | 1 |
| Ishihara, S | 1 |
| Amano, Y | 1 |
| Hattori, S | 1 |
| Mine, S | 3 |
| Iida, T | 3 |
| Tabata, T | 3 |
| Kishikawa, H | 1 |
| Tanaka, Y | 3 |
| Demirkan, K | 1 |
| Bozkurt, B | 1 |
| Karakaya, G | 1 |
| Kalyoncu, AF | 1 |
| Miki, M | 1 |
| Kim, J | 1 |
| Ogai, A | 1 |
| Nakatani, S | 1 |
| Hashimura, K | 1 |
| Kanzaki, H | 1 |
| Komamura, K | 1 |
| Asakura, M | 1 |
| Asanuma, H | 1 |
| Kitamura, S | 1 |
| Tomoike, H | 1 |
| Kitakaze, M | 1 |
| Konturek, JW | 1 |
| Beneke, M | 1 |
| Koppermann, R | 1 |
| Petersen-Braun, M | 1 |
| Weingärtner, U | 1 |
| Miner, PB | 1 |
| Allgood, LD | 1 |
| Grender, JM | 1 |
| Okada, Y | 1 |
| Malcolm, WF | 1 |
| Gantz, M | 1 |
| Martin, RJ | 1 |
| Goldstein, RF | 1 |
| Goldberg, RN | 1 |
| Cotten, CM | 1 |
| Turton, DB | 1 |
| Shakir, KM | 1 |
| Hanson, DG | 1 |
| Kamel, PL | 1 |
| Kahrilas, PJ | 1 |
| Heckers, H | 1 |
| Lübbecke, F | 1 |
| Kelly, DA | 1 |
| Okoth, FA | 1 |
| Lule, GN | 1 |
| Ogutu, EO | 1 |
| Pilczer, S | 1 |
| Dubois, C | 1 |
| Ducrotté, P | 1 |
| Guillemot, F | 1 |
| Elouaer-Blanc, L | 1 |
| Hirschauer, C | 1 |
| Thorel, JM | 1 |
| Petit, A | 1 |
| Hochain, P | 1 |
| Michel, P | 1 |
| Cortot, A | 1 |
| Colin, R | 1 |
| Marrero, JM | 1 |
| de Caestecker, JS | 1 |
| Maxwell, JD | 1 |
| Berenson, MM | 1 |
| Berlin, RG | 2 |
| Snapinn, S | 1 |
| Cagliola, A | 2 |
| Golochevskaia, VS | 1 |
| Kallal, SM | 1 |
| Lee, M | 1 |
| Paradowski, L | 1 |
| Salomon, A | 1 |
| Szelag, A | 1 |
| Hatlebakk, JG | 1 |
| Berstad, A | 1 |
| Engzelius, JM | 1 |
| Solhaug, JH | 1 |
| Knapstad, LJ | 1 |
| Kjaersgaard, P | 1 |
| Abidin, ZU | 1 |
| Ivashkin, VT | 1 |
| Sheptulin, AA | 1 |
| Trukhmanov, AS | 1 |
| Okhlobystin, AV | 1 |
| Fujisaki, T | 1 |
| Matsuoka, H | 1 |
| Yamada, S | 1 |
| Morimoto, I | 1 |
| Eto, S | 1 |
| Aibe, T | 1 |
| Morisset, M | 1 |
| Moneret-Vautrin, DA | 1 |
| Loppinet, V | 1 |
| Grandidier, S | 1 |
| Ivanova, S | 1 |
| Gavrilova, V | 1 |
| Dimitrov, L | 1 |
| Ray, SW | 1 |
| Secrest, J | 1 |
| Ch'ien, AP | 1 |
| Corey, RS | 1 |
| Wesdorp, IC | 1 |
| Michocki, RJ | 1 |
| Richardson, JP | 1 |
| Fennerty, MB | 1 |
| Sampliner, RE | 1 |
| Sabesin, SM | 1 |
| Humphries, TJ | 4 |
| Bradstreet, DC | 1 |
| Walton-Bowen, KL | 1 |
| Zaidi, S | 1 |
| Robinsen, M | 1 |
| Decktor, DL | 1 |
| Stone, RC | 1 |
| Pevelery, M | 1 |
| Barden, P | 1 |
| Moyer, R | 1 |
| Holt, S | 1 |
| Root, J | 1 |
| Hufnagel, K | 2 |
| Bianchi Porro, G | 1 |
| Pace, F | 1 |
| Sangaletti, O | 1 |
| Root, JK | 1 |
| Fiorucci, S | 1 |
| Santucci, L | 1 |
| Perrone, E | 1 |
| Abbritti, F | 1 |
| Morelli, A | 1 |
| Orr, WC | 1 |
| Robinson, MG | 1 |
| Antonello, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| YM1170 Phase 2/3 Study: A Double Blind, Placebo Controlled, Group-comparison Study in Patients With Non-erosive Gastroesophageal Reflux Disease[NCT00141960] | Phase 2/Phase 3 | 480 participants | Interventional | 2005-09-30 | Completed | ||
| Effects of Non-nutritive Sucking on Gastroesophageal Reflux, Apneas and Bradycardias in Symptomatic Preterm Infants.[NCT02023216] | 30 participants (Actual) | Observational | 2013-05-31 | Completed | |||
| Generic Database: A Survey of Morbidity and Mortality in Very Low Birth Weight Infants[NCT00063063] | 80,000 participants (Anticipated) | Observational | 1987-01-31 | Recruiting | |||
| Effect of Different Modalities of Enteral Tube Feeding (ETF) on Gastroesophageal Reflux (GER) in Symptomatic Preterm Infants[NCT02837627] | 31 participants (Actual) | Observational | 2016-01-01 | Completed | |||
| Follow-up Visit of High Risk Infants[NCT00009633] | 68,000 participants (Anticipated) | Observational | 1993-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for famotidine and Esophageal Reflux
| Article | Year |
|---|---|
Comparative effectiveness of histamine-2 receptor antagonists as short-term therapy for gastro-esophageal reflux disease: a network meta-analysis.
Topics: Adult; Dose-Response Relationship, Drug; Famotidine; Gastroesophageal Reflux; Histamine H2 Antagonis | 2016 |
[Treatment of gastroesophageal reflux disease].
Topics: Anti-Ulcer Agents; Famotidine; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Life Style | 2003 |
[Evaluation of the efficacy and the cost-effectiveness of maintenance treatment of gastroesophageal reflux disease: proton pump inhibitor versus histamine-2-receptor antagonist].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Drug Therapy, Combin | 2004 |
Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esophagitis, Peptic; Famotidine; Gastroesophageal Reflux; H | 2005 |
Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anaphylaxis; Anti-Ulcer Agents; Benzimidazoles; Famotidine; | 2006 |
Do H2 receptor antagonists have a therapeutic role in childhood?
Topics: Adolescent; Child; Child, Preschool; Cimetidine; Cystic Fibrosis; Drug Interactions; Famotidine; Gas | 1994 |
[Clinical aspects of Kvamatel (famotidine) administration].
Topics: Anti-Ulcer Agents; Famotidine; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Peptic Ulc | 1996 |
Thrombotic thrombo-cytopenic purpura associated with histamine H2-receptor antagonist therapy.
Topics: Adrenal Cortex Hormones; Blood Transfusion; Combined Modality Therapy; Famotidine; Gastroesophageal | 1996 |
Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Benzimidazoles; Cimetidine; Cisapride; Domperidon | 1996 |
Managing gastroesophageal reflux disease.
Topics: Anti-Ulcer Agents; Diagnosis, Differential; Famotidine; Gastroesophageal Reflux; Humans; Outcome Ass | 2002 |
Famotidine in gastroesophageal reflux disease (GERD).
Topics: Cimetidine; Esophagitis, Peptic; Famotidine; Gastroesophageal Reflux; Humans; Ranitidine | 1992 |
The clinical use of histamine-2 receptor antagonists.
Topics: Cimetidine; Drug Evaluation; Famotidine; Gastroesophageal Reflux; Humans; Nizatidine; Peptic Ulcer; | 1992 |
27 trials available for famotidine and Esophageal Reflux
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease.
Topics: Double-Blind Method; Famotidine; Female; Gastroesophageal Reflux; Heartburn; Histamine H2 Antagonist | 2008 |
Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aspirin; Cross-Over Studies; Esophagus; Famotidine; Female; | 2012 |
Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS).
Topics: Algorithms; Benzamides; Diterpenes; Dose-Response Relationship, Drug; Dyspepsia; Famotidine; Gastroe | 2012 |
Randomized comparative study of omeprazole and famotidine in reflux esophagitis.
Topics: Aged; Drug Evaluation; Enzyme Inhibitors; Esophagitis, Peptic; Esophagoscopy; Famotidine; Female; Ga | 2002 |
[Efficacy of gastrosidine (famotidine) in the treatment of gastroesophageal reflux at the reflux esophagitis stage].
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Esophagitis, Peptic; Famotidine; Female; Gastroesophagea | 2002 |
Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial.
Topics: Administration, Oral; Famotidine; Female; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; | 2003 |
[Effect of H2-blockers and proton pump inhibitors on intragastric acidity and intraesophageal pH in patients with gastroesophageal reflux disease].
Topics: Drug Administration Schedule; Endoscopy, Digestive System; Famotidine; Gastric Acid; Gastric Acidity | 2004 |
Pharmacokinetics of famotidine in infants.
Topics: Administration, Oral; Area Under Curve; Biological Availability; Famotidine; Female; Gastroesophagea | 2005 |
Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
Topics: Analysis of Variance; Anti-Ulcer Agents; Drug Therapy, Combination; Famotidine; Female; Gastroesopha | 2005 |
Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Famotidine; Female; Gastroesophageal Reflux; Helicobacter Infections; Helicobacte | 2005 |
Comparative study of the speed of acid-suppressing effects of oral administration of cimetidine and famotidine.
Topics: Adult; Chromatography, High Pressure Liquid; Cimetidine; Cross-Over Studies; Famotidine; Follow-Up S | 2005 |
Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Comorbidity; Cross-Over Studies; D | 2005 |
Management of symptoms in step-down therapy of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Deglutition Disorders; Endosonography; Enzyme Inhibit | 2005 |
Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies.
Topics: Aged; Cardiac Output, Low; Chronic Disease; Famotidine; Female; Gastroesophageal Reflux; Histamine H | 2006 |
The efficacy of hydrotalcite compared with OTC famotidine in the on-demand treatment of gastroesophageal reflux disease: a non-inferiority trial.
Topics: Adult; Aged; Aluminum Hydroxide; Antacids; Anti-Ulcer Agents; Demography; Famotidine; Female; Gastro | 2007 |
Increased esophageal mucosal/submucosal blood flow in patients with gastroesophageal reflux disease: normalization by treatment with a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Endoscopy, Gastrointestinal | 2008 |
[Symptomatic therapy with famotidine in non-erosive gastro-esophageal reflux. Results of an open multicenter study].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Endoscopy, Gastrointestinal; Famotidine; Femal | 1995 |
Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease.
Topics: Adult; Aged; Double-Blind Method; Esophagus; Famotidine; Female; Gastroesophageal Reflux; Heartburn; | 1994 |
Randomized, placebo-controlled comparison of famotidine 20 mg b.d. or 40 mg b.d. in patients with erosive oesophagitis.
Topics: Administration, Oral; Adult; Double-Blind Method; Esophagitis; Famotidine; Female; Gastroesophageal | 1994 |
[The effect of cimetidine and famotidine on esophageal motility].
Topics: Adult; Cimetidine; Duodenal Ulcer; Esophagus; Famotidine; Female; Gastroesophageal Reflux; Histamine | 1996 |
Ranitidine effervescent and famotidine wafer in the relief of episodic symptoms of gastro-oesophageal reflux disease.
Topics: Administration, Oral; Famotidine; Female; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; | 1997 |
Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Double-Blind Method; Endosonograph | 2000 |
[Intravenous treatment with quamatel in reflux-esophagus and erosive gastritis].
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Esophagitis, Peptic; Famotidine; Female; Gastritis; Gast | 2000 |
Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Esophago | 1991 |
Famotidine (20 mg) b.d. relieves gastrooesophageal reflux symptoms in patients without erosive oesophagitis. Famotidine/GERD Investigation Group.
Topics: Administration, Oral; Adult; Antacids; Double-Blind Method; Drug Administration Schedule; Esophagiti | 1991 |
Gastric and esophageal acidity during continuous treatment with H2-antagonists in uncomplicated esophagitis.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Esophagitis; Esophagus; Famotidine; Fema | 1989 |
Dose--response effect of famotidine on patterns of gastro-oesophageal reflux.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Famotidine; Gastric Acidity Dete | 1988 |
22 other studies available for famotidine and Esophageal Reflux
| Article | Year |
|---|---|
Role of Famotidine and Other Acid Reflux Medications for SARS-CoV-2: A Pilot Study.
Topics: Adult; COVID-19; Famotidine; Gastroesophageal Reflux; Humans; Pilot Projects; SARS-CoV-2 | 2023 |
More Than Just Heartburn: Does Famotidine Effectively Treat Patients with COVID-19?
Topics: COVID-19; Famotidine; Gastroesophageal Reflux; Heartburn; Humans; SARS-CoV-2 | 2021 |
No association between chronic use of ranitidine, compared with omeprazole or famotidine, and gastrointestinal malignancies.
Topics: Animals; Famotidine; Gastroesophageal Reflux; Gastrointestinal Neoplasms; Humans; Omeprazole; Raniti | 2021 |
Iron-deficiency anemia caused by a proton pump inhibitor.
Topics: Anemia, Iron-Deficiency; Famotidine; Gastroesophageal Reflux; Humans; Male; Middle Aged; Proton Pump | 2014 |
[Gastroesophageal reflux disease in preschool children with asthma].
Topics: Androstadienes; Asthma; Child, Preschool; Diagnosis, Differential; Esophageal pH Monitoring; Famotid | 2008 |
Physiological and clinical characteristics of gastroesophageal reflux after congenital diaphragmatic hernia repair.
Topics: Antacids; Anti-Ulcer Agents; Combined Modality Therapy; Drugs, Chinese Herbal; Esophageal Sphincter, | 2010 |
Should fundoplication be added at the time of gastrostomy placement in patients who are neurologically impaired?
Topics: Adolescent; Anti-Ulcer Agents; Child; Child, Preschool; Combined Modality Therapy; Drugs, Chinese He | 2010 |
In vitro effects of famotidine and ranitidine on lower esophageal sphincter tone in rats.
Topics: Animals; Disease Models, Animal; Esophageal Sphincter, Lower; Famotidine; Gastroesophageal Reflux; H | 2012 |
The effect of famotidine on gastroesophageal and duodeno-gastro-esophageal refluxes in critically ill patients.
Topics: Adult; Aged; Bile Reflux; Critical Illness; Famotidine; Female; Gastric Acid; Gastroesophageal Reflu | 2003 |
Minimal change oesophagitis: a disease with characteristic differences to erosive oesophagitis.
Topics: Adult; Aged; Anti-Ulcer Agents; Bile; Color; Esophagitis; Esophagoscopy; Famotidine; Female; Gastrit | 2005 |
Tolerance to H2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease.
Topics: Adult; Dose-Response Relationship, Drug; Drug Tolerance; Famotidine; Gastric Acid; Gastric Acidity D | 2006 |
Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment.
Topics: Administration, Oral; Adult; Anti-Ulcer Agents; Cross-Over Studies; Dose-Response Relationship, Drug | 2007 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Galactorrhea caused by esophagitis.
Topics: Adult; Anti-Ulcer Agents; Bethanechol; Esophagitis; Famotidine; Female; Galactorrhea; Gastroesophage | 1995 |
Outcomes of antireflux therapy for the treatment of chronic laryngitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Chronic Disease; Famotidine; Female; Gastroesopha | 1995 |
Famotidine in the management of gastro-oesophageal reflux.
Topics: Adult; Endoscopy, Gastrointestinal; Esophagitis, Peptic; Famotidine; Female; Follow-Up Studies; Gast | 1994 |
Comparison of omeprazole and famotidine on esophageal pH in patients with moderate to severe esophagitis: a cross-over study.
Topics: Adult; Aged; Esophagitis; Esophagus; Famotidine; Female; Gastric Acid; Gastroesophageal Reflux; Huma | 1994 |
[Role of 24 hour intraesophageal pH monitoring in diagnosis of gastroesophageal reflux and assessment of drug effectiveness].
Topics: Adult; Anti-Ulcer Agents; Circadian Rhythm; Esophagus; Famotidine; Female; Follow-Up Studies; Gastro | 1999 |
Cross-allergy to ranitidine and nizatidine.
Topics: Adult; Anti-Ulcer Agents; Cross Reactions; Drug Hypersensitivity; Famotidine; Gastroesophageal Reflu | 2000 |
Medical therapy for gastroesophageal reflux disease. Not all treatments are equal!
Topics: Drug Administration Schedule; Famotidine; Gastroesophageal Reflux; Humans; Omeprazole | 1991 |
Pattern of acid reflux in patients with reflux esophagitis 'resistant' to H2-receptor antagonists.
Topics: Esophagitis, Peptic; Famotidine; Female; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; | 1990 |
Successful drug-specific chronotherapy with the H2 blocker famotidine in the symptomatic relief of gastroesophageal reflux disease.
Topics: Drug Administration Schedule; Famotidine; Gastroesophageal Reflux; Humans | 1991 |